Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients.

Next Previous
Trial Profile

Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients.

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACE inhibitors; Alpha adrenergic receptor antagonists; Angiotensin receptor antagonists; Antihypertensives; Beta-adrenergic receptor antagonists; Calcium channel antagonists; Enalapril; Isradipine; Propranolol
  • Indications Hypertension
  • Focus Therapeutic Use

Most Recent Events

  • 13 Apr 2021 Biomarkers information updated
  • 22 Apr 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
  • 26 Sep 2012 Planned End Date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top